Residual virulence and immunogenicity of CGV26 and CGV2631 B. melitensis Rev. 1 deletion mutant strains in sheep after subcutaneous or conjunctival vaccination.
The CGV26 and CGV2631 strains are novel engineered Brucella melitensis Rev.1 mutant strains deleted for the bp26 gene or for both bp26 and omp31 genes, respectively, coding for proteins of diagnostic significance. The residual virulence and immunogenicity of both mutants were compared to the parental Rev.1 strain in sheep after subcutaneous or conjunctival vaccination. The deletion of the bp26 gene or both bp26 and omp31 genes had no significant effect on the intracellular survival of the Rev.1 strain in ovine macrophage cultures. The kinetics of infection induced by both mutants in sheep was similar to the Rev.1 strain, and inoculation by the subcutaneous route produced wider and more generalized infections than the conjunctival route. All strains were cleared from lymph nodes and organs within 3 months after inoculation. The CGV26 and CGV2631 mutants induced both specific systemic antibody response and lymphoproliferation in sheep. The kinetics of the responses induced by the mutants was quite similar to that of the parental Rev.1 strain, except for the intensity of the lymphoproliferative response, which was attenuated for the CGV2631 mutant. In conclusion, the residual virulence of both CGV26 and CGV2631 mutants in sheep was similar to that of the parental Rev.1 vaccine strain. These mutants induced also significant specific antibody and cell-mediated immunity in sheep and are suitable to be evaluated as potential vaccine candidates against B. melitensis and B. ovis infections in sheep.
Guilloteau
Laurence A
LA
Laboratoire de Pathologie Infectieuse et Immunologie, Institut National de Recherche Agronomique, Centre de Tours-Nouzilly, F-37380 Nouzilly, France. laurence.guilloteau@tours.inra.fr
Laroucau
Karine
K
Olivier
Michel
M
Grillo
Maria Jesus
MJ
Marin
Clara M
CM
Verger
Jean-Michel
JM
Blasco
Jose-Maria
JM
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D002004:Brucella Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D042061:Brucella ovis / Q000276:immunology* / Q000472:pathogenicity; D002006:Brucellosis / Q000517:prevention & control / Q000662:veterinary*; D003228:Conjunctiva; D005260:Female; D007279:Injections, Subcutaneous; D008213:Lymphocyte Activation; D008264:Macrophages / Q000382:microbiology; D009154:Mutation; D012756:Sheep; D012757:Sheep Diseases / Q000517:prevention & control*; D014611:Vaccination / Q000662:veterinary*; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D014774:Virulence
D000907:Antibodies, Bacterial; D002004:Brucella Vaccine; D014614:Vaccines, Synthetic